Tyrosine kinase inhibitorPhase 3 trialInvestigational
Sorafenib
How it works
Sorafenib is a small molecule that blocks multiple tyrosine kinases, including VEGFR-2, which is involved in tumor growth and angiogenesis.
Cancer types
Lung Cancer— All patients
Pancreatic Cancer— All patients
Efficacy
Studies show that sorafenib can improve overall survival in patients with pancreatic cancer, with a median overall survival of approximately 6.4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining Sorafenib and Atorvastatin to Treat Colorectal Cancer | Colorectal Cancer | lab-study | The combination of ATST + SOR showed a tumor growth inhibition rate of ~ 80%. | Source → |
| Improving Sorafenib Delivery for Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Testing Riluzole and Sorafenib in Advanced Solid Tumors and Melanoma | Melanoma | phase-1 | — | Source → |
| Testing Combination Therapy for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Targeted Nanoparticles Deliver Cancer Drug More Effectively | Breast Cancer | animal-study | Treatment with the nanoparticles resulted in a 66.1% decrease in tumor volumes in mice. | Source → |
| Dammarolic Acid Enhances Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Combining Polydatin and Sorafenib May Help Fight Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Adding sorafenib to chemotherapy improves outcomes in some AML patients | Leukemia | phase-1/2 | One-year overall survival and event-free survival were 80% and 76%, respectively. | Source → |
| Combining Gossypol and Sorafenib May Improve Lung Cancer Treatment | Lung Cancer | lab-study | The combination treatment showed a synergistic cytotoxic effect, with a dose reduction index (DRI) up to 3.86. | Source → |
| Rare Cancer Treatment Shows Promise with Combination Therapy | Leukemia | lab-study | — | Source → |
| Sorafenib Improves Outcomes for Children with High-Risk Leukemia | Leukemia | phase-2 | Risk of an event was approximately two-fold higher in HAR /ITD+ patients who did not receive sorafenib (event-free survival from study entry: hazard ratio [HR] 2.37, 95% CI, 1.45 to 3.88, < .001, disease-free survival from complete remission: HR 2.28, 95% CI, 1.08 to 4.82, = .032, relapse risk from complete remission: HR 3.03, 95% CI 1.31 to 7.04, = .010). | Source → |
| Combining Light Therapy and Medication to Enhance Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.